2021 Q4 Form 10-Q Financial Statement
#000156459022004972 Filed on February 14, 2022
Income Statement
| Concept | 2021 Q4 | 2021 Q3 | 2020 Q4 |
|---|---|---|---|
| Revenue | $10.41M | $10.53M | $10.15M |
| YoY Change | 2.57% | 0.99% | -20.73% |
| Cost Of Revenue | $4.016M | $4.073M | $3.918M |
| YoY Change | 2.5% | 0.07% | -23.13% |
| Gross Profit | $6.395M | $6.452M | $6.232M |
| YoY Change | 2.62% | 1.57% | -19.15% |
| Gross Profit Margin | 61.43% | 61.3% | 61.4% |
| Selling, General & Admin | $6.000M | $6.030M | $5.255M |
| YoY Change | 14.18% | 11.13% | -13.61% |
| % of Gross Profit | 93.82% | 93.46% | 84.32% |
| Research & Development | |||
| YoY Change | |||
| % of Gross Profit | |||
| Depreciation & Amortization | $366.0K | $333.0K | $318.0K |
| YoY Change | 15.09% | 11.0% | -9.14% |
| % of Gross Profit | 5.72% | 5.16% | 5.1% |
| Operating Expenses | $7.467M | $7.445M | $6.486M |
| YoY Change | 15.12% | 11.54% | -12.67% |
| Operating Profit | -$1.072M | -$993.0K | -$254.0K |
| YoY Change | 322.05% | 207.43% | -190.39% |
| Interest Expense | -$3.000K | -$14.00K | -$7.000K |
| YoY Change | -57.14% | 100.0% | -275.0% |
| % of Operating Profit | |||
| Other Income/Expense, Net | |||
| YoY Change | |||
| Pretax Income | -$454.0K | $2.008M | $3.161M |
| YoY Change | -114.36% | -790.03% | 1457.14% |
| Income Tax | $23.00K | $2.000K | $15.00K |
| % Of Pretax Income | 0.1% | 0.47% | |
| Net Earnings | -$593.0K | $1.939M | $3.074M |
| YoY Change | -119.29% | -670.29% | -7419.05% |
| Net Earnings / Revenue | -5.7% | 18.42% | 30.29% |
| Basic Earnings Per Share | -$0.09 | $0.28 | |
| Diluted Earnings Per Share | -$85.36K | $273.3K | $445.2K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 6.947M | 6.924M | |
| Diluted Shares Outstanding | 6.947M | 7.095M |
Balance Sheet
| Concept | 2021 Q4 | 2021 Q3 | 2020 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $8.315M | $8.933M | $11.24M |
| YoY Change | -26.03% | -21.66% | 144.0% |
| Cash & Equivalents | $8.315M | $8.933M | $11.24M |
| Short-Term Investments | |||
| Other Short-Term Assets | $1.928M | $2.291M | $2.288M |
| YoY Change | -15.73% | -6.68% | 9.26% |
| Inventory | $1.894M | $1.917M | $1.927M |
| Prepaid Expenses | |||
| Receivables | $4.359M | $4.687M | $4.074M |
| Other Receivables | $3.586M | $3.586M | $0.00 |
| Total Short-Term Assets | $20.08M | $21.41M | $19.53M |
| YoY Change | 2.83% | 6.97% | 35.78% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $8.425M | $6.920M | $7.114M |
| YoY Change | 18.43% | 6.54% | 7.69% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | $1.220M | ||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $462.0K | $649.0K | $638.0K |
| YoY Change | -27.59% | 33.81% | 65.71% |
| Total Long-Term Assets | $10.10M | $9.954M | $8.992M |
| YoY Change | 12.33% | 20.99% | 6.55% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $20.08M | $21.41M | $19.53M |
| Total Long-Term Assets | $10.10M | $9.954M | $8.992M |
| Total Assets | $30.18M | $31.37M | $28.52M |
| YoY Change | 5.82% | 11.06% | 24.97% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $1.161M | $1.698M | $1.394M |
| YoY Change | -16.71% | 5.2% | -15.36% |
| Accrued Expenses | $5.044M | $5.296M | $4.578M |
| YoY Change | 10.18% | 18.61% | 2.51% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $38.00K | $37.00K | $1.582M |
| YoY Change | -97.6% | -97.36% | 383.79% |
| Total Short-Term Liabilities | $6.870M | $7.545M | $9.061M |
| YoY Change | -24.18% | -37.58% | 40.7% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $36.00K | $44.00K | $1.759M |
| YoY Change | -97.95% | -97.74% | 1499.09% |
| Other Long-Term Liabilities | $1.070M | $1.030M | $1.225M |
| YoY Change | -12.65% | 495.38% | -18.93% |
| Total Long-Term Liabilities | $1.106M | $1.074M | $2.984M |
| YoY Change | -62.94% | -61.0% | 84.08% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $6.870M | $7.545M | $9.061M |
| Total Long-Term Liabilities | $1.106M | $1.074M | $2.984M |
| Total Liabilities | $7.976M | $8.619M | $12.05M |
| YoY Change | -33.78% | -41.93% | 49.42% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | |||
| YoY Change | |||
| Common Stock | |||
| YoY Change | |||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $22.21M | $22.75M | $16.48M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $30.18M | $31.37M | $28.52M |
| YoY Change | 5.82% | 11.06% | 24.97% |
Cashflow Statement
| Concept | 2021 Q4 | 2021 Q3 | 2020 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$593.0K | $1.939M | $3.074M |
| YoY Change | -119.29% | -670.29% | -7419.05% |
| Depreciation, Depletion And Amortization | $366.0K | $333.0K | $318.0K |
| YoY Change | 15.09% | 11.0% | -9.14% |
| Cash From Operating Activities | $210.0K | -$334.0K | $220.0K |
| YoY Change | -4.55% | -141.03% | -163.22% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $826.0K | $692.0K | $405.0K |
| YoY Change | 103.95% | 16.3% | 36.36% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $6.000K | $5.000K | $32.00K |
| YoY Change | -81.25% | -37.5% | -84.24% |
| Cash From Investing Activities | -$820.0K | -$687.0K | -$373.0K |
| YoY Change | 119.84% | 17.04% | 296.81% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | $8.000K | ||
| YoY Change | 0.0% | ||
| Cash From Financing Activities | -8.000K | -8.000K | -9.000K |
| YoY Change | -11.11% | 0.0% | -99.66% |
| NET CHANGE | |||
| Cash From Operating Activities | 210.0K | -334.0K | 220.0K |
| Cash From Investing Activities | -820.0K | -687.0K | -373.0K |
| Cash From Financing Activities | -8.000K | -8.000K | -9.000K |
| Net Change In Cash | -618.0K | -1.029M | -162.0K |
| YoY Change | 281.48% | -569.86% | -94.71% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | $210.0K | -$334.0K | $220.0K |
| Capital Expenditures | $826.0K | $692.0K | $405.0K |
| Free Cash Flow | -$616.0K | -$1.026M | -$185.0K |
| YoY Change | 232.97% | -568.49% | -71.32% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2021Q4 | us-gaap |
Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2021-01-31#OtherAssets | |
| CY2021Q2 | us-gaap |
Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2021-01-31#OtherAssets | |
| CY2021Q4 | us-gaap |
Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2021-01-31#DebtCurrent | |
| CY2021Q2 | us-gaap |
Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2021-01-31#DebtCurrent | |
| CY2021Q4 | us-gaap |
Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2021-01-31#LongTermDebtNoncurrent | |
| CY2021Q2 | us-gaap |
Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2021-01-31#LongTermDebtNoncurrent | |
| us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
290000 | ||
| ssy |
Forgiveness Of Ppp Loans And Accrued Interest
ForgivenessOfPPPLoansAndAccruedInterest
|
0 | ||
| ssy |
Federal Stimulus Provider Relief Funds
FederalStimulusProviderReliefFunds
|
3448000 | ||
| us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
-17000 | ||
| CY2021Q4 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
120000 | |
| CY2020Q4 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
120000 | |
| us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
290000 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-577000 | ||
| ssy |
Federal Stimulus Provider Relief Funds
FederalStimulusProviderReliefFunds
|
614000 | ||
| CY2021Q4 | ssy |
Forgiveness Of Ppp Loans And Accrued Interest
ForgivenessOfPPPLoansAndAccruedInterest
|
0 | |
| CY2020Q4 | ssy |
Forgiveness Of Ppp Loans And Accrued Interest
ForgivenessOfPPPLoansAndAccruedInterest
|
0 | |
| ssy |
Forgiveness Of Ppp Loans And Accrued Interest
ForgivenessOfPPPLoansAndAccruedInterest
|
3010000 | ||
| us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
-14000 | ||
| CY2021Q4 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-454000 | |
| CY2020Q4 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
3161000 | |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
1554000 | ||
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
2870000 | ||
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
25000 | ||
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
15000 | ||
| us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
1529000 | ||
| us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
2855000 | ||
| us-gaap |
Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
|
0.22 | ||
| us-gaap |
Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
|
-183000 | ||
| us-gaap |
Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
|
-121000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
1346000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
2734000 | ||
| us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
0 | ||
| us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
0 | ||
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
1346000 | ||
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
2734000 | ||
| us-gaap |
Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
|
0.41 | ||
| us-gaap |
Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
|
0.22 | ||
| us-gaap |
Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
|
0.41 | ||
| us-gaap |
Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
|
-0.03 | ||
| us-gaap |
Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
|
-0.02 | ||
| us-gaap |
Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
|
-0.03 | ||
| us-gaap |
Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
|
-0.02 | ||
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.19 | ||
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.40 | ||
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.19 | ||
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.40 | ||
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
6935000 | ||
| CY2020Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
11184000 | |
| us-gaap |
Labor And Related Expense
LaborAndRelatedExpense
|
8611000 | ||
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 2. – Business Operations </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Healthcare Services</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Health Services segment includes the following:</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">A subsidiary which owns and operates Trace Regional Medical Center and Trace Extended Care and Rehabilitation (“Trace”), an 84 licensed-bed acute care hospital, located in Houston, Mississippi, which includes an 26-bed geriatric psychology unit (“GPU”), a 66-bed nursing home and four clinics. This facility focuses primarily on senior healthcare services.</span><span style="font-family:Times New Roman;"> </span><span style="font-family:Times New Roman;"> </span><span style="font-family:Times New Roman;"> </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">A subsidiary, SunLink Health Systems Technology (“SHS Technology”), which provides information technology (IT) services to outside customers and to SunLink subsidiaries.</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-size:10pt;font-family:'Times New Roman'">A</span><span style="font-size:10pt;font-family:'Times New Roman'"> </span><span style="font-family:Times New Roman;">subsidiary which owns approximately five (5) acres of unimproved land in Houston, Mississippi, and</span> </p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:3.12%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="color:#000000;"> </span><span style="font-family:'Times New Roman';color:#000000;"><span style="font-size:10pt;font-family:'Times New Roman'">A</span><span style="font-size:10pt;font-family:'Times New Roman'"> </span></span><span style="color:#000000;">subsidiary which owns approximately 25 acres of unimproved land in Ellijay, Georgia.</span></p></td></tr></table></div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pharmacy</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Pharmacy segment is composed of three operational areas which are conducted primarily in markets in Louisiana:</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Retail pharmacy products and services, consisting of retail pharmacy sales conducted in Crowley, Louisiana. </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-family:Times New Roman;">Institutional pharmacy services consisting of the provision of specialty and non-specialty</span><span style="font-family:Times New Roman;"> p</span><span style="font-family:Times New Roman;">harmaceutical and biological products to institutional clients or to patients in institutional settings, such as nursing homes, assisted living facilities, behavioral and specialty hospitals, hospice, and correctional facilities</span><span style="font-family:Times New Roman;">; and,</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-size:10pt;font-family:'Times New Roman'"> </span><span style="font-size:10pt;font-family:'Times New Roman'"> </span><span style="font-family:Times New Roman;">Durable medical equipment products and services (“DME”), consisting primarily of the sale and rental of products for institutional clients or to patients in institutional settings and patient-administered home care.</span></p></td></tr></table></div> <p style="text-align:justify;Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#212529;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">COVID-19 Pandemic and CARES Act Funding</span></p> <p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.91%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 was declared a global pandemic by the World Health Organization on March 11, 2020. We have been monitoring the COVID-19 pandemic and its impact on our operations, and we have taken significant steps intended to minimize the risk to our employees and patients. Certain employees have been working remotely, but we believe these remote work arrangements have not materially affected our ability to maintain critical business operations, which are being conducted substantially in accordance with our understanding of applicable government health and safety protocols and guidance issued in response to the COVID-19 pandemic, although such protocols and guidance have been subject to frequent changes and at times, have been unclear. Nevertheless, as in many healthcare environments, we have experienced COVID-19 illness, including deaths, and some employees have tested positive and were placed on leave or in quarantine. We believe the effect of the COVID-19 pandemic and public and certain governmental responses to it have negatively affected our last eight quarter’s results. </p> <p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:6.25%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In late December 2020, we began receiving allotments of COVID-19 vaccine and have vaccinated patients, providers, employees, and staff in accordance with the protocols and guidelines in the states where we operate. Not all such individuals have been vaccinated to date and some individuals have not consented to vaccination. The Company and its subsidiaries are currently developing and will implement plans to vaccinate employees to the extent required by the final rules issued by CMS. The Company believes the vaccine mandates, together with the current state of the labor market, have resulted in the loss of staff, including clinical staff, and have negatively affected the Company’s ability to maintain the desired levels of service in some areas. </p> <p style="margin-bottom:14pt;margin-top:0pt;margin-left:0.3%;margin-right:0.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.25%;">In our Healthcare businesses, we have experienced material reductions in demand and net revenues due to the COVID-19 pandemic. There continues to be reduced current demand for certain hospital services, and for extended care, rehabilitation center and nursing home admissions, and clinic visits. The availability and cost of medical supplies have adversely affected our Healthcare businesses, and we continue to monitor supplies and seek additional sources of many supply items. A reduction in the availability of qualified employees has also occurred, and, despite good faith efforts to do so, we have not yet been able to rehire or fully replace staff which were previously furloughed, laid off or retired.</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.3%;margin-right:0.17%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.25%;"><span style="color:#000000;">Since the beginning of the COVID-19 pandemic, our Pharmacy business has experienced reduced sales trends in certain areas, increased costs and reduced staff. Certain of our primary physician referral sources have been operating at reduced capacity, and until these referral sources resume operating at full capacity, we believe the COVID-19 pandemic will continue adversely to affect the demand for DME products and Retail and Institutional Pharmacy drugs and products. Reductions in employee hours have been made in response to the lower demand. Extended care facilities and rehabilitation centers, nursing homes and other customers of our Institutional Pharmacy services continue to be adversely affected by the COVID-19 pandemic. Our Institutional Pharmacy services have experienced increased costs and operational inefficiencies due to measures taken to protect our employees and by access controls and other restrictions implemented by our institutional customers. The impact of the COVID-19 pandemic has also negatively affected our supply processes, especially with respect to access to respiratory equipment and certain personal protective equipment and cleaning products.</span></p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.91%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.3%;margin-right:0.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.25%;">Our Healthcare and Pharmacy segments have received approximately $6,173 in general and targeted Provider Relief Funds ("PRF") during the period April 1, 2020 through December 31, 2021 under the CARES Act, which was enacted in March 2020 in response to the COVID-19 pandemic. The PRF distributions have been accounted for as government grants, and a total of $5,546 have been recognized since April l, 2020 as other income under the gain contingency recognition method.</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.3%;margin-right:0.17%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.3%;margin-right:0.17%;text-indent:5.88%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the quarter ended June 30, 2020, our Healthcare and Pharmacy segments received $3,234 in PPP loans provided under the CARES Act. These loans were forgivable upon compliance with conditions specified under the PPP loan program. As of December 31, 2021, all our PPP loans have been forgiven. </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.3%;margin-right:0.17%;text-indent:6.32%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:13pt;margin-top:0pt;margin-left:0.3%;margin-right:0.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.25%;">PRF distributions are not subject to repayment provided we are able to attest to and comply with the terms and conditions of the funding, including demonstrating that the funds received have been used for designated, allowable healthcare-related expenses and capital expenditures attributable to COVID-19 and for Lost Revenues as defined by HHS. We continue to monitor compliance with the terms and conditions of the PRF and the impact of the pandemic on our revenues and expenses. If we are unable to attest to or comply with current or future terms and conditions, and there is no assurance we will be able to do so, our ability to retain some or all of the PRF received may be impacted, and we may have to return the unutilized portion of those funds, if any, in the future.</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.3%;margin-right:0.17%;text-indent:6.32%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Taxpayer Certainty and Disaster Tax Relief Act of 2020, enacted December 27, 2020, made a number of changes to employer retention tax credits previously made available under the CARES Act, including modifying and extending the Employee Retention Credit ("ERC") for the six calendar months ending June 30, 2021. As a result of such legislation, the Company qualified for ERC for the first and second calendar quarters of 2021 due to the decrease in its gross receipts and has applied for and recognized as income ERC of $3,586 through amended quarterly payroll tax filings for the applicable quarters.</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.3%;margin-right:0.17%;text-indent:6.32%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:20pt;margin-top:0pt;margin-left:0.3%;margin-right:0.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.25%;">The Company is unable to determine the extent to which the COVID-19 pandemic going forward will continue to affect its assets and operations. Our ability to make estimates of the effect of the COVID-19 pandemic on revenues, expenses or changes in accounting judgments that have had or are reasonably likely to have a material effect on our financial statements is currently limited. The nature and extent of the effect of the COVID-19 pandemic on our balance sheet and results of operations will depend on the severity and length of the pandemic, including the infection rate, severity rate and mortality rate of existing and potential new variants: government actions to mitigate the pandemic's effect; regulatory changes in response to the pandemic, especially those that affect our hospital, extended care, rehabilitation center, nursing home, clinics, and our pharmacy operations; existing and potential government assistance that may be provided; and the requirements of PRF receipts, including our ability to retain such PRF received.</p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:3.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> | ||
| ssy |
Employee Retention Credit Amending Quarterly Payroll Tax Filing Amount
EmployeeRetentionCreditAmendingQuarterlyPayrollTaxFilingAmount
|
3586000 | ||
| CY2021Q2 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
20810000 | |
| CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-340000 | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1518000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1000000 | ||
| us-gaap |
Proceeds From Sale Of Other Assets Investing Activities
ProceedsFromSaleOfOtherAssetsInvestingActivities
|
11000 | ||
| us-gaap |
Proceeds From Sale Of Other Assets Investing Activities
ProceedsFromSaleOfOtherAssetsInvestingActivities
|
40000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-1507000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-960000 | ||
| us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
16000 | ||
| us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
17000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-16000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-17000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-1647000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
57000 | ||
| CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
8315000 | |
| CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
11241000 | |
| ssy |
Interest Paid Received Net
InterestPaidReceivedNet
|
7000 | ||
| ssy |
Interest Paid Received Net
InterestPaidReceivedNet
|
-1000 | ||
| us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
2000 | ||
| us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
308000 | ||
| ssy |
Right Of Use Asset Obtained In Exchange For Lease Liability
RightOfUseAssetObtainedInExchangeForLeaseLiability
|
35000 | ||
| ssy |
Right Of Use Asset Obtained In Exchange For Lease Liability
RightOfUseAssetObtainedInExchangeForLeaseLiability
|
691000 | ||
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
6899000 | ||
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
7099000 | ||
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
6904000 | ||
| CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
1939000 | |
| CY2021Q3 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
22749000 | |
| CY2021Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-593000 | |
| CY2021Q4 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
51000 | |
| CY2021Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
22207000 | |
| CY2020Q3 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
13403000 | |
| CY2020Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
3074000 | |
| CY2020Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
16477000 | |
| CY2020Q2 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
13743000 | |
| CY2021Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
9962000 | |
| us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
20572000 | ||
| CY2021Q4 | ssy |
Health Care Organization Significant Change In Estimates
HealthCareOrganizationSignificantChangeInEstimates
|
186000 | |
| CY2021Q4 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
0 | |
| CY2020Q4 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
0 | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
0 | ||
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
0 | ||
| CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
0 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
0 | ||
| us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
30000 | ||
| CY2021Q4 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
30000 | |
| CY2021Q4 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
10411000 | |
| CY2020Q4 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
10150000 | |
| us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
20936000 | ||
| ssy |
Health Care Organization Significant Change In Estimates
HealthCareOrganizationSignificantChangeInEstimates
|
186000 | ||
| CY2020Q4 | ssy |
Health Care Organization Significant Change In Estimates
HealthCareOrganizationSignificantChangeInEstimates
|
69000 | |
| ssy |
Health Care Organization Significant Change In Estimates
HealthCareOrganizationSignificantChangeInEstimates
|
69000 | ||
| CY2021Q4 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
6000 | |
| CY2020Q4 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
7000 | |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
13000 | ||
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
14000 | ||
| CY2021Q4 | ssy |
Finance Lease Obligations
FinanceLeaseObligations
|
74000 | |
| CY2021Q2 | ssy |
Finance Lease Obligations
FinanceLeaseObligations
|
89000 | |
| CY2021Q4 | us-gaap |
Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
|
38000 | |
| CY2021Q2 | us-gaap |
Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
|
3009000 | |
| CY2021Q4 | us-gaap |
Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
|
36000 | |
| CY2021Q2 | us-gaap |
Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
|
52000 | |
| CY2021Q4 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
23000 | |
| CY2021Q4 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
23000 | |
| CY2021Q4 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
23000 | |
| CY2020Q4 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
15000 | |
| CY2020Q4 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
15000 | |
| CY2020Q4 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
15000 | |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
25000 | ||
| us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
25000 | ||
| us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
25000 | ||
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
15000 | ||
| us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
15000 | ||
| us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
15000 | ||
| CY2021Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
7121000 | |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | |
| CY2021Q4 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
16957000 | |
| CY2021Q4 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
16957000 | |
| ssy |
Net Operating Loss Carry Forwards Expire Period
NetOperatingLossCarryForwardsExpirePeriod
|
2023 through fiscal 2038 | ||
| CY2021Q4 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
125000 | |
| CY2020Q4 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
142000 | |
| us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
250000 | ||
| CY2021Q4 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
2000 | |
| CY2020Q4 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
2000 | |
| us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
3000 | ||
| us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
4000 | ||
| us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
260000 | ||
| CY2021Q4 | ssy |
Short Term Lease Cost Income
ShortTermLeaseCostIncome
|
-5000 | |
| CY2020Q4 | ssy |
Short Term Lease Cost Income
ShortTermLeaseCostIncome
|
-22000 | |
| ssy |
Operating Variable Lease Cost
OperatingVariableLeaseCost
|
1000 | ||
| CY2021Q4 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
120000 | |
| us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
290000 | ||
| CY2020Q4 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
9000 | |
| us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
18000 | ||
| us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
18000 | ||
| CY2021Q4 | ssy |
Finance Lease Cost
FinanceLeaseCost
|
11000 | |
| CY2020Q4 | ssy |
Finance Lease Cost
FinanceLeaseCost
|
11000 | |
| ssy |
Finance Lease Cost
FinanceLeaseCost
|
21000 | ||
| ssy |
Finance Lease Cost
FinanceLeaseCost
|
22000 | ||
| CY2021Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
1043000 | |
| CY2021Q2 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
1251000 | |
| CY2021Q4 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
203000 | |
| CY2021Q2 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
203000 | |
| CY2021Q4 | us-gaap |
Property Plant And Equipment Owned Accumulated Depreciation
PropertyPlantAndEquipmentOwnedAccumulatedDepreciation
|
88000 | |
| CY2021Q2 | us-gaap |
Property Plant And Equipment Owned Accumulated Depreciation
PropertyPlantAndEquipmentOwnedAccumulatedDepreciation
|
72000 | |
| CY2021Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
38000 | |
| CY2021Q2 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
37000 | |
| CY2021Q4 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
36000 | |
| CY2021Q2 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
52000 | |
| CY2021Q4 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
126000 | |
| CY2020Q4 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
141000 | |
| CY2021Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0115 | |
| CY2020Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0349 | |
| CY2021Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0115 | |
| CY2020Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0349 | |
| CY2021Q4 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.0654 | |
| CY2020Q4 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.0654 | |
| CY2021Q4 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.0654 | |
| CY2020Q4 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.0654 | |
| us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
252000 | ||
| CY2020Q4 | ssy |
Operating Cash Flows From Finance Lease
OperatingCashFlowsFromFinanceLease
|
2000 | |
| ssy |
Operating Cash Flows From Finance Lease
OperatingCashFlowsFromFinanceLease
|
3000 | ||
| ssy |
Operating Cash Flows From Finance Lease
OperatingCashFlowsFromFinanceLease
|
4000 | ||
| CY2021Q4 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
9000 | |
| CY2020Q4 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
9000 | |
| us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
18000 | ||
| us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
17000 | ||
| CY2021Q4 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
0 | |
| CY2020Q4 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
682000 | |
| us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
35000 | ||
| us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
691000 | ||
| CY2021Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P1Y10M24D | |
| CY2020Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P2Y10M24D | |
| CY2021Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P1Y10M24D | |
| CY2020Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P2Y10M24D | |
| CY2021Q4 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P3Y10M17D | |
| CY2020Q4 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P4Y3M10D | |
| CY2021Q4 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P3Y10M17D | |
| CY2020Q4 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P4Y3M10D | |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
308000 | |
| CY2021Q4 | us-gaap |
Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
|
42000 | |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
265000 | |
| CY2021Q4 | us-gaap |
Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
|
38000 | |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
252000 | |
| CY2021Q4 | us-gaap |
Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
|
0 | |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
221000 | |
| CY2021Q4 | us-gaap |
Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
|
0 | |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
35000 | |
| CY2021Q4 | us-gaap |
Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
|
0 | |
| CY2021Q4 | ssy |
Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
|
5000 | |
| CY2021Q4 | ssy |
Finance Lease Liability Payments Due After Year Four
FinanceLeaseLiabilityPaymentsDueAfterYearFour
|
0 | |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
1086000 | |
| CY2021Q4 | us-gaap |
Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
|
80000 | |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
22000 | |
| CY2021Q4 | us-gaap |
Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
|
6000 | |
| CY2021Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
1064000 | |
| CY2021Q4 | us-gaap |
Finance Lease Liability
FinanceLeaseLiability
|
74000 | |
| CY2021Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
299000 | |
| CY2021Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
38000 | |
| CY2021Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
765000 | |
| CY2021Q4 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
36000 | |
| ssy |
Number Of Taxing Authorities
NumberOfTaxingAuthorities
|
2 | ||
| CY2020Q2 | us-gaap |
Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority
IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority
|
359000 | |
| CY2021Q4 | us-gaap |
Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
|
2278000 | |
| CY2021Q2 | us-gaap |
Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
|
1966000 | |
| us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
2 | ||
| CY2021Q4 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
10411000 | |
| CY2021Q4 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-1072000 | |
| CY2021Q4 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
366000 | |
| CY2021Q4 | us-gaap |
Assets
Assets
|
30183000 | |
| CY2021Q4 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
826000 | |
| CY2020Q4 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
10150000 | |
| CY2020Q4 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-254000 | |
| CY2020Q4 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
318000 | |
| CY2020Q4 | us-gaap |
Assets
Assets
|
28522000 | |
| CY2020Q4 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
405000 | |
| us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
20936000 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2065000 | ||
| us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
699000 | ||
| CY2021Q4 | us-gaap |
Assets
Assets
|
30183000 | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1518000 | ||
| us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
20572000 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-577000 | ||
| us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
618000 | ||
| CY2020Q4 | us-gaap |
Assets
Assets
|
28522000 | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1000000 |
